Stock LWK1 EFFECTOR THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News eFFECTOR Therapeutics, Inc. Deutsche Boerse AG

Equities

LWK1

US28202V1089

Real-time Estimate Tradegate
Other stock markets
 04:32:23 2024-07-01 EDT 		5-day change 1st Jan Change
0.266 EUR -75.26% Intraday chart for eFFECTOR Therapeutics, Inc. -8.12% -88.97%
06-24 Sector Update: Health Care Stocks Rise in Late Afternoon Trading MT
06-24 Top Midday Decliners MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
EFFECTOR Therapeutics : Accelaration/Increase of Financial Obligation Form 8 K
PU
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
MT
Top Midday Decliners
MT
Sector Update: Health Care Stocks Advance Monday Afternoon
MT
EFFECTOR Therapeutics to Shut Down Operations, Seeking Strategic Alternatives
MT
EFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
AQ
EFFECTOR Therapeutics, Inc Appoints Craig R. Jalbert as CEO
CI
EFFECTOR Therapeutics, Inc. Appoints Craig R. Jalbert as President, Treasurer and Secretary, and Sole Member of the Board
CI
EFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
CI
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Health Care Down on Retreat From Risk -- Health Care Roundup
DJ
Top Midday Decliners
MT
EFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
AQ
EFFECTOR Therapeutics, Inc. Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
CI
Top Premarket Decliners
MT
EFFECTOR Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
EFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
AQ
EFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
AQ
Transcript : EFFECTOR Therapeutics, Inc. - Special Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EFTR Stock
  4. LWK1 Stock
  5. News eFFECTOR Therapeutics, Inc.